Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Gut microbiome composition alteration" does not refer to a single molecular target but rather describes changes—often termed "dysbiosis"—in the community structure of microorganisms residing in the gastrointestinal tract. These alterations can be caused by factors such as diet, antibiotics, environmental exposures, age, genetics, stressors, and underlying health conditions. The gut microbiota plays essential roles in digestion; nutrient absorption; energy harvest; vitamin synthesis; modulation of inflammation; maintenance of intestinal barrier integrity; regulation via the gut-brain axis affecting neurological health; and protection against pathogens.[1][3][4] Persistent alterations are linked to various diseases including inflammatory bowel disease,[1] metabolic disorders like diabetes,[5] neurodegenerative conditions such as Alzheimer’s,[4] liver diseases,[1] cardiovascular complications,[5], among others. Therapeutic strategies do not target "gut microbiome composition alteration" directly as one would a receptor or enzyme but instead aim to restore healthy balance through interventions like probiotics/prebiotics administration,[7], fecal transplants,[2], dietary modification,[1], lifestyle changes,[4], or selective use/reduction of antibiotics.[6]. While these approaches show promise across multiple indications—including gastrointestinal disorders like IBS [7], neurodegeneration [4], diabetes [5], radiation-induced injury [3], etc.—the field faces challenges regarding efficacy reproducibility between individuals/populations and potential safety risks associated with manipulating complex microbial ecosystems.[2]. Because "gut microbiome composition alteration" is not itself a discrete molecular entity but rather an ecosystem-level phenomenon/process/state—and because it cannot be classified under standard molecular families—it is considered an incorrect entry if intended as a canonical drug target.
Mechanisms for drugs/interventions targeting this process include: - Restoration of microbial diversity and balance via probiotics/prebiotics/fecal transplant[2][4][7] - Suppression or elimination of pathogenic bacteria with antibiotics or bacteriotherapy[2] - Modulation of microbial metabolites that influence host metabolism and immune function (e.g., short-chain fatty acids, sphingolipids)[3][4]
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiome composition alteration (null).